Stocks
China Biologic Products Holdings Financial Statements (CBPO) |
||||||||||
| China Biologic Products Holdingssmart-lab.ru | % | 2019Q4 | 2020Q1 | 2020Q2 | 2020Q3 | 2020Q4 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.03.2020 | 20.05.2020 | 17.08.2020 | 30.09.2020 | 31.12.2020 | 31.12.2020 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 102.2 | 162.6 | 111.1 | 138.5 | 112.1 | 524.4 | |||
| Operating Income, bln rub | 18.6 | 68.0 | 42.7 | 52.0 | 32.6 | 195.4 | ||||
| EBITDA, bln rub | ? | 24.3 | 71.7 | 48.9 | 56.1 | 38.7 | 215.5 | |||
| Net profit, bln rub | ? | 12.5 | 53.4 | 35.7 | 39.5 | 23.7 | 152.3 | |||
| OCF, bln rub | ? | 72.9 | 75.7 | 59.7 | 53.0 | 70.0 | 258.5 | |||
| CAPEX, bln rub | ? | 3.17 | 3.24 | 3.81 | 7.08 | 6.91 | 21.0 | |||
| FCF, bln rub | ? | 69.7 | 72.5 | 55.9 | 45.9 | 63.1 | 237.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 45.4 | 33.0 | 33.7 | 40.4 | 42.0 | 149.1 | ||||
| Cost of production, bln rub | 38.2 | 61.6 | 34.7 | 46.1 | 37.5 | 179.9 | ||||
| R&D, bln rub | 4.28 | 1.74 | 2.83 | 1.17 | 2.84 | 8.58 | ||||
| Interest expenses, bln rub | 0.241 | 0.105 | 0.074 | 0.079 | 0.066 | 0.324 | ||||
| Assets, bln rub | 1 938 | 1 985 | 2 024 | 2 140 | 2 260 | 2 260 | ||||
| Net Assets, bln rub | ? | 1 775 | 1 810 | 1 859 | 1 976 | 2 082 | 2 082 | |||
| Debt, bln rub | 1.17 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Cash, bln rub | 927.3 | 991.6 | 1 041 | 1 103 | 1 193 | 1 193 | ||||
| Net debt, bln rub | -926.1 | -991.6 | -1 041 | -1 103 | -1 193 | -1 193 | ||||
| Ordinary share price, rub | 116.4 | 107.9 | 102.2 | 111.1 | 118.1 | 117.9 | ||||
| Number of ordinary shares, mln | 38.5 | 38.5 | 38.5 | 38.7 | 38.7 | 38.7 | ||||
| Market cap, bln rub | 4 477 | 4 152 | 3 936 | 4 300 | 4 570 | 4 562 | ||||
| EV, bln rub | ? | 3 551 | 3 160 | 2 895 | 3 197 | 3 377 | 3 369 | |||
| Book value, bln rub | 1 394 | 1 437 | 1 487 | 1 590 | 1 682 | 1 682 | ||||
| EPS, rub | ? | 0.32 | 1.39 | 0.93 | 1.02 | 0.61 | 3.94 | |||
| FCF/share, rub | 1.81 | 1.88 | 1.45 | 1.19 | 1.63 | 6.14 | ||||
| BV/share, rub | 36.2 | 37.4 | 38.6 | 41.1 | 43.5 | 43.5 | ||||
| EBITDA margin, % | ? | 23.8% | 44.1% | 44.0% | 40.5% | 34.5% | 41.1% | |||
| Net margin, % | ? | 12.2% | 32.8% | 32.1% | 28.5% | 21.1% | 29.0% | |||
| FCF yield, % | ? | 4.58% | 6.10% | 6.46% | 5.68% | 5.20% | 5.21% | |||
| ROE, % | ? | 7.82% | 8.53% | 7.99% | 7.14% | 7.32% | 7.32% | |||
| ROA, % | ? | 7.16% | 7.78% | 7.34% | 6.59% | 6.74% | 6.74% | |||
| P/E | ? | 32.3 | 26.9 | 26.5 | 30.5 | 30.0 | 30.0 | |||
| P/FCF | 21.8 | 16.4 | 15.5 | 17.6 | 19.2 | 19.2 | ||||
| P/S | ? | 8.89 | 7.74 | 7.69 | 8.36 | 8.71 | 8.70 | |||
| P/BV | ? | 3.21 | 2.89 | 2.65 | 2.70 | 2.72 | 2.71 | |||
| EV/EBITDA | ? | 18.3 | 14.8 | 14.0 | 15.9 | 15.7 | 15.6 | |||
| Debt/EBITDA | -4.78 | -4.65 | -5.05 | -5.49 | -5.54 | -5.54 | ||||
| R&D/CAPEX, % | 135.0% | 53.8% | 74.2% | 16.6% | 41.1% | 40.8% | ||||
| CAPEX/Revenue, % | 3.11% | 1.99% | 3.43% | 5.11% | 6.16% | 4.01% | ||||
| China Biologic Products Holdings shareholders | ||||||||||
